The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2013 Financial Results on July 31, 2013

Wednesday, July 17, 2013

Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2013 Financial Results on July 31, 2013

09:00 EDT Wednesday, July 17, 2013

BOTHELL, Wash. (Business Wire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2013 financial results on Wednesday, July 31, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Wednesday, July 31, 2013
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

  • Telephone 877-941-9205 (domestic) or 480-629-9771 (international); conference ID 4630720
  • Webcast available at http://www.seattlegenetics.com/ in the Investors and News section

REPLAY access

  • Telephone replay will be available beginning at approximately 3:30 p.m. PT on Wednesday, July 31, 2013 through 5:00 p.m. PT on Friday, August 2, 2013 by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4630720
  • Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com/ in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company's lead program, ADCETRIS® (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional approval from the European Commission in October 2012. Seattle Genetics also has five other clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME, SGN-CD19A and SGN-CD33A. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Celldex, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at www.seattlegenetics.com.

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Customer Service
Advertising Privacy
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections